1. Isidori A. et al. Iron toxicity - Its effect on the bone marrow.//Blood Rev. England, 2018. Vol. 32, N 6. P. 473 - 479.

2. Marsh J.C.W., Kulasekararaj A.G. Management of the refractory aplastic anemia patient: what are the options?//Blood. 2013. Vol. 122, N 22. P. 3561 - 3567.

3. Frickhofen N. et al. Antithymocyte globulin with or without cyclosporin A: 11-Year follow-up of a randomized trial comparing treatments of aplastic anemia//Blood. 2003. Vol. 101, N 4. P. 1236 - 1242.

4. Kulasekararaj A.G. et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome//Blood. 2014. Vol. 124, N 17. P. 2698 - 2704.

5. Afable M.G., Tiu R. V, Maciejewski J.P. Clonal Evolution in Aplastic Anemia//Hematology. 2011. N 1. P. 90 - 95.

6. Pu J.J. et al. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia//Eur. J. Haematol. 2011. Vol. 87, N 1. P. 37 - 45.

7. G. et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors//Lancet. 1996. Vol. 348, N 9027. P. 573 - 577.

8. Kulagin A. et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: Results of two-centre prospective study//Br. J. Haematol. 2014. Vol. 164, N 4. P. 546 - 554.

9. Li Y. et al. Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: A single-center experience//Ann. Hematol. 2011. Vol. 90, N 5. P. 529 - 537.

10. Кулагин А.Д., Лисуков И.А., Птушкин В.В., Шилова Е.Р., Цветаева Н.В. М.Е.А. Национальные рекомендации по диагностике и лечению проксизмальной ночной гемоглобинурии//Онкогематология. 2014. Vol. 2. P. 20 - 28.

11. Kaufman D.W. et al. Relative incidence of agranulocytosis and aplastic anemia//Am. J. Hematol. 2006.

12. Михайлова Е.А., Фидарова З.Т., и др. Протокол комбинированной иммуносупрессивной терапии больных апластической анемией (редакция 2024 г.)//Алгоритмы диагностики и протоколы лечения заболеваний системы крови: в двух томах. Под ред. Е.Н. Паровичниковой. Том 1. - М.: Практика, 2024. стр. 271 - 287.

13. Killick S.B. et al. Guidelines for the diagnosis and management of adult aplastic anaemia.//Br. J. Haematol. England, 2016. Vol. 172, N 2. P. 187 - 207.

14. Soulier J. Fanconi anemia.//Hematology Am. Soc. Hematol. Educ. Program. 2011. Vol. 2011. P. 492 - 497.

15. Camitta B.M. What is the definition of cure for aplastic anemia?//Acta Haematologica. 2000. Vol. 103, N 1. P. 16 - 18.

16. Dokal I. Dyskeratosis congenita.//Hematology. 2011. Vol. 2011. P. 480 - 486.

17. Kulasekararaj A, Cavenagh J, Dokal I, Foukaneli T, Gandhi S, Garg M, et al. Guidelines for the diagnosis and management of adultaplastic anaemia: A British Society for HaematologyGuideline. Br J Haematol. 2024; 204(3): 784 - 804. https://doi.org/10.1111/bjh.19236

18. Peslak S.A., Olson T., Babushok D.V. Diagnosis and Treatment of Aplastic Anemia//Current Treatment Options in Oncology. Springer New York LLC, 2017. Vol. 18, N 12.

19. Пантелеев М.А. et al. Практическая коагулология. 2010. 192 p.

20. Hayward C.P.M. How I investigate for bleeding disorders//International Journal of Laboratory Hematology. Blackwell Publishing Ltd, 2018. Vol. 40. P. 6 - 14.

21. Nielsen P. et al. Iron Stores in Patients with Myelodysplasia and Aplastic Anemia.//Blood. 2006. Vol. 108, N 11. P. 3726 - 3726.

22. DeZern A.E., Churpek J.E. Approach to the diagnosis of aplastic anemia//Blood Adv. American Society of Hematology, 2021. Vol. 5, N 12. P. 2660 - 2671.

23. Kelsey P. et al. Guidelines for the use of platelet transfusions//Br. J. Haematol. 2003. Vol. 122, N 1. P. 10 - 23.

24. Maciejewski J.P., Mufti G.J. Whole genome scanning as a cytogenetic tool in hematologic malignancies//Blood. 2008. Vol. 112, N 4. P. 965 - 974.

25. Maciejewski J.P. et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia//Blood. 2002. Vol. 99, N 9. P. 3129 - 3135.

26. Gupta V. et al. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults//Br. J. Haematol. 2006. Vol. 134, N 1. P. 95 - 99.

27. Miano M., Dufour C. The diagnosis and treatment of aplastic anemia: a review//Int. J. Hematol. 2015. Vol. 101, N 6. P. 527 - 535.

28. Dumitriu B. et al. Red cells, iron, and erythropoiesis: Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia//Blood. 2015. Vol. 125, N 4. P. 706 - 709.

29. Jerez A. et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients//Blood. 2013. Vol. 122, N 14. P. 2453 - 2459.

30. Du Y. et al. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload.//Acta Haematol. Switzerland, 2017. Vol. 138, N 2. P. 119 - 128.

31. Borowitz M.J. et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry//Cytom. Part B - Clin. Cytom. Wiley-Liss Inc., 2010. Vol. 78, N 4. P. 211 - 230.

32. Ogawa S. Clonal hematopoiesis in acquired aplastic anemia//Blood. 2016. Vol. 128, N 3. P. 337 - 347.

33. Parker C.J. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria.//Hematology. United States, 2016. Vol. 2016, N 1. P. 208 - 216.

34. Brown K.E. et al. Hepatitis-associated aplastic anemia//N. Engl. J. Med. 1997. Vol. 336, N 15. P. 1059 - 1064.

35. Карагюлян С.Р. et al. Технические сложности выполнения спленэктомии при заболеваниях системы крови//Клиническая онкогематология. 2017. Vol. 10, N 1. P. 101 - 107.

36. Alter B.P. Diagnosis, genetics, and management of inherited bone marrow failure syndromes.//Hematology. 2007. P. 29 - 39.

37. Михайлова Е.А. et al. Клинические рекомендации по диагностике и лечению апластической анемии (редакция 2019 г.)//Гематология и трансфузилогия. 2020. Vol. 65, N 2. P. 208 - 226.

38. Smith L.G. Reactions to blood transfusions//Am. J. Nurs. 1984. Vol. 84, N 9. P. 1096 - 1101.

39. Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation.//Hematology. 2012. P. 292 - 300.

40. Townsley D.M., Winkler T. Nontransplant therapy for bone marrow failure//ASH Educ. Progr. B. 2016. Vol. 2016, N 1. P. 83 - 89.

41. Desmond R. et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug//Blood. 2014. Vol. 123, N 12. P. 1818 - 1825.

42. Desmond R. et al. Eltrombopag in Aplastic Anemia//Seminars in Hematology. 2015. Vol. 52, N 1. P. 31 - 37.

43. Fattizzo B. et al. Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag.//American journal of hematology. United States, 2019.

44. Lee J.W. et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: A subgroup analysis of 116 patients from the EPIC trial//Blood. 2010. Vol. 116, N 14. P. 2448 - 2454.

45. Bacigalupo A. et al. Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy - The European Group for blood and marrow transplantation experience//Semin. Hematol. 2000. Vol. 37, N 1. P. 69 - 80.

46. Bacigalupo A. et al. Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin//Br. J. Haematol. 1989. Vol. 73, N 1. P. 121 - 126.

47. Rosenfeld S. et al. Antithymocyte Globulin and Cyclosporine for Severe Aplastic Anemia: Association between Hematologic Response and Long-term Outcome//J. Am. Med. Assoc. 2003. Vol. 289, N 9. P. 1130 - 1135.

48. Михайлова Е.А., Фидарова З.Т., Устинова Е.Н., Троицкая В.В., Гальцева И.В., Шитарева И.В. и др. Комбинированная иммуносупрессивная терапия у больных апластической анемией: эффективность повторных курсов.//Гематология и трансфузиология. 2014. Vol. 59, N 4. P. 11 - 18.

49. Scheinberg P. et al. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia//Br. J. Haematol. 2009. Vol. 144, N 2. P. 206 - 216.

50. C., Dowsett M., Reis-Filho J.S. Revisiting the technical validation of tumour biomarker assays: How to open a Pandora's box//BMC Med. 2011. Vol. 9.

51. Bacigalupo A. et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT SAA Working Party//Br. J. Haematol. 1988. Vol. 70, N 2. P. 177 - 182.

52. Scheinberg P. et al. Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia//Am. J. Hematol. 2014. Vol. 89, N 5. P. 467 - 469.

53. Peffault de Latour R. et al. Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia.//Am. J. Hematol. United States, 2018. Vol. 93, N 5. P. 635 - 642.

54. Михайлова Е.А. et al. Комбинированная иммуносупрессивная терапия больных апластической анемией: повторные курсы антитимоцитарного глобулина//ГЕМАТОЛОГИЯ И ТРАНСФУЗИОЛОГИЯ. 2014. Vol. 59, N 4. P. 11 - 18.

55. Bacigalupo A. How I treat acquired aplastic anemia//Blood. 2017. Vol. 129, N 11. P. 1428 - 1436.

56. Scheinberg P., Young N.S. How I treat acquired aplastic anemia.//Blood. 2012. Vol. 120, N 6. P. 1185 - 1196.

57. Scheinberg P. et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia//N. Engl. J. Med. 2011. Vol. 365, N 5. P. 430 - 438.

58. Gafter-Gvili A. et al. ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia--systematic review and meta-analysis//Acta Haematol. Acta Haematol, 2008. Vol. 120, N 4. P. 237 - 243.

59. Yamazaki H. et al. Cyclosporine Therapy for Acquired Aplastic Anemia: Predictive Factors for the Response and Long-term Prognosis//Int. J. Hematol. 2007 853. Springer, 2007. Vol. 85, N 3. P. 186 - 190.

60. Hong Y. et al. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.//Clin. Drug Investig. 2019. Vol. 39, N 2. P. 141 - 156.

61. Olnes M.J. et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia.//N. Engl. J. Med. 2012. Vol. 367, N 1. P. 11 - 19.

62. Dietz A.C. et al. Evolving Hematopoietic Stem Cell Transplantation Strategies in Severe Aplastic Anemia//Curr. Opin. Pediatr. NIH Public Access, 2016. Vol. 28, N 1. P. 3.

63. Park Y.B. et al. Incidence and etiology of overt gastrointestinal bleeding in adult patients with aplastic anemia//Dig. Dis. Sci. Dig Dis Sci, 2010. Vol. 55, N 1. P. 73 - 81.

64. Burget D.W., Chiverton S.G., Hunt R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression//Gastroenterology. Gastroenterology, 1990. Vol. 99, N 2. P. 345 - 351.

65. Ивашкин В.Т. et al. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества).//Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020. Vol. 30, N 1. P. 49 - 70.

66. Scally B. et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials//Lancet Gastroenterol. Hepatol. Elsevier Ltd, 2018. Vol. 3, N 4. P. 231 - 241.

67. B. et al. Supportive care in severe and very severe aplastic anemia//Bone Marrow Transplantation. 2013. Vol. 48, N 2. P. 168 - 173.

68. Fan E., Brodie D., Slutsky A.S. Acute respiratory distress syndrome advances in diagnosis and treatment//JAMA - Journal of the American Medical Association. American Medical Association, 2018. Vol. 319, N 7. P. 698 - 710.

69. Young P. et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: The SPLIT randomized clinical trial//JAMA - J. Am. Med. Assoc. American Medical Association, 2015. Vol. 314, N 16. P. 1701 - 1710.

70. Hoorn E.J. Intravenous fluids: balancing solutions//Journal of Nephrology. Springer New York LLC, 2017. Vol. 30, N 4. P. 485 - 492.

71. Arends J. et al. ESPEN guidelines on nutrition in cancer patients//Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, N 1. P. 11 - 48.

72. Шихмирзаев Т.А. et al. Фармакопрофилактика трансфузионных реакций//Вестник Национального медико-хирургического Центра им. Н.И. Пирогова. 2018. Vol. 13, N 2. P. 95 - 99.

73. Аксельрод Б.А. et al. Клиническое использование эритроцитсодержащих компонентов донорской крови//Гематология и трансфузиология. 2018. Vol. 63, N 4. P. 372 - 435.

74. Криволапов Ю.А. Технические аспекты выполнения трепанобиопсий костного мозга. Клиническая онкогематология 2014; 7: 290 - 295//Клиническая онкогематология. 2014. Vol. 7. P. 290 - 295.

75. Wang J. et al. Diagnostic utility of bilateral bone marrow examination: Significance of morphologic and ancillary technique study in malignancy//Cancer. Cancer, 2002. Vol. 94, N 5. P. 1522 - 1531.

76. SPIRIN M., GALSTYAN G., DROKOV M. Central venous access in lymphoma patients (pts) with superior vena cava syndrome (SVCS)//INTENSIVE CARE Med. Exp. 2019. Vol. 7, N Suppl. 3:001341. P. 388 - 389.

77. Pluschnig U. et al. Extravasation emergencies: state-of-the-art management and progress in clinical research.//Memo. Springer, 2016. Vol. 9, N 4. P. 226 - 230.

78. Zeidler K. et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia.//Transfusion. 2011. Vol. 51, N 11. P. 2269 - 2276.

79. Zerati A.E. et al. Totally implantable venous catheters: history, implantation technique and complications.//J Vasc Bras. 2017. Vol. 16, N 2. P. 128 - 139.

80. Gow K.W., Tapper D., Hickman R.O. Between the lines: The 50th anniversary of long-term central venous catheters//Am. J. Surg. Elsevier Ltd, 2017. Vol. 213, N 5. P. 837 - 848.

81. Yeral M. et al. Tunnelled central venous catheter-related problems in the early phase of haematopoietic stem cell transplantation and effects on transplant outcome.//Turkish J. Haematol. Off. J. Turkish Soc. Haematol. Galenos Yayinevi, 2015. Vol. 32, N 1. P. 51 - 57.

82. Maki D.G., Kluger D.M., Crnich C.J. The Risk of Bloodstream Infection in Adults With Different Intravascular Devices: A Systematic Review of 200 Published Prospective Studies//Mayo Clin. Proc. Elsevier, 2006. Vol. 81, N 9. P. 1159 - 1171.

83. Hamilton H. Central Venous Catheters/ed. Bodenham A.R. Oxford, UK: Wiley-Blackwell, 2009.

84. Biffi R. Introduction and Overview of PICC History//Peripherally Inserted Central Venous Catheters. Milano: Springer Milan, 2014. P. 1 - 6.

85. Linenberger M.L. Catheter-related thrombosis: risks, diagnosis, and management.//J. Natl. Compr. Canc. Netw. 2006. Vol. 4, N 9. P. 889 - 901.

86. Lee A.Y.Y., Kamphuisen P.W. Epidemiology and prevention of catheter-related thrombosis in patients with cancer//J. Thromb. Haemost. 2012. N 10. P. 1491 - 1499.

87. Цепенщинков Л., Лядов В.К. Периферически имплантируемый центральный венозный катетер: обзор литературы.//Клиническая онкогематология. 2014. Vol. 7, N 2. P. 220 - 228.

88. Linder L.E. et al. Material thrombogenicity in central venous catheterization: a comparison between soft, antebrachial catheters of silicone elastomer and polyurethane.//JPEN. J. Parenter. Enteral Nutr. 1984. Vol. 8, N 4. P. 399 - 406.

89. Watters V.A., Grant J.P. Use of Electrocardiogram to Position Right Atrial Catheters During Surgery//Ann. Surg. Vol. 225, N 2. P. 165 - 171.

90. Taal M.W., Chesterton L.J., McIntyre C.W. Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis//Nephrol. Dial. Transplant. Oxford University Press, 2004. Vol. 19, N 6. P. 1542 - 1545.

91. Lobato E.B. et al. Cross-sectional area of the right and left internal jugular veins.//J. Cardiothorac. Vasc. Anesth. 1999. Vol. 13, N 2. P. 136 - 138.

92. Червонцева А.М. Повреждение сосудистого эндотелия в процессе лечения острых миелоидных лейкозов. 2008.

93. Багирова Н.С. Инфекции, связанные с внутрисосудистыми устройствами: терминология, диагностика, профилактика и терапия//Злокачественные опухоли. 2014. N 3. P. 164 - 171.

94. Bannon M.P., Heller S.F., Rivera M. Anatomic considerations for central venous cannulation.//Risk Manag. Healthc. Policy. Dove Press, 2011. Vol. 4. P. 27 - 39.

95. Milling T.J. et al. Randomized, controlled clinical trial of point-of-care limited ultrasonography assistance of central venous cannulation: The Third Sonography Outcomes Assessment Program (SOAP-3) Trial*//Crit. Care Med. 2005. Vol. 33, N 8. P. 1764 - 1769.

96. Зозуля Н.И., Кумскова М.А. Протокол диагностики и лечения гемофилии.//Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Том 1. Практика/ed. Савченко В.Г. Москва, 2018. P. 333 - 358.

97. Галстян Г.М. НАРУШЕНИЯ ГЕМОСТАЗА, ОБУСЛОВЛЕННЫЕ ДЕФИЦИТОМ ВИТАМИН К-ЗАВИСИМЫХ ФАКТОРОВ СВЕРТЫВАНИЯ КРОВИ - ПАТОГЕНЕЗ, СПОСОБЫ КОРРЕКЦИИ И РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ.//Гематология и трансфузиология. 2012. Vol. 27, N 2. P. 7 - 21.

98. Habermalz B. et al. Laparoscopic splenectomy: The clinical practice guidelines of the European Association for Endoscopic Surgery (EAES)//Surgical Endoscopy and Other Interventional Techniques. Surg Endosc, 2008. Vol. 22, N 4. P. 821 - 848.

99. Воробьев А.И. et al. Критические состояния при гемобластозах (типичные формы и выживаемость в условиях отделения реанимации).//Терапевтический архив. 1993. Vol. 65, N 7. P. 3 - 6.

100. Галстян Г.М., Городецкий В.М. Опыт работы отделения реанимации и интенсивной терапии ФГБУ ГНЦ МЗиСР РФ//Клиническая онкогематология. 2011. Vol. 4, N 1. P. 75 - 78.

101. Lamia B. et al. Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU//Intensive Care Med. Intensive Care Med, 2006. Vol. 32, N 10. P. 1560 - 1568.

102. Evison J.M. et al. Intensive care unit admission in patients with haematological disease: incidence, outcome and prognostic factors. 2001.

103. Silfvast T. et al. Multiple organ failure and outcome of critically ill patients with haematological malignancy//Acta Anaesthesiol. Scand. Acta Anaesthesiol Scand, 2003. Vol. 47, N 3. P. 301 - 306.

104. Benoit D.D. et al. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication//Crit. Care Med. Crit Care Med, 2003. Vol. 31, N 1. P. 104 - 112.

105. Schellongowski P. et al. Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience//Haematologica. 2011. Vol. 96, N 2. P. 231 - 237.

106. M.G. et al. Hematologic malignancies in the medical intensive care unit - Outcomes and prognostic factors//Hematology. Maney Publishing, 2015. Vol. 20, N 5. P. 247 - 253.

107. Jackson K. et al. Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit//Leuk. Lymphoma. Leuk Lymphoma, 2013. Vol. 55, N April. P. 1 - 8.

108. Ahmed T. et al. Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit//Leuk. Res. Elsevier Ltd, 2017. Vol. 62. P. 51 - 55.

109. Протоколы трансплантации аллогенных гепомоэтических стволовых клеток. Под ред. В.Г. Савченко. М.: Практика, 2020. 320 p.

110. Willis L. et al. Recent developments in drug therapy for aplastic anemia//Ann. Pharmacother. Ann Pharmacother, 2014. Vol. 48, N 11. P. 1469 - 1478.

111. Bonfim C. et al. Bone Marrow Transplantation (BMT) for heavily Transfused Patients (pts) with Severe Aplastic Anemia (SAA): 147 pts treated at the same institution with Busulfan (BU) + Cyclophosphamide (CY)//Biol. Blood Marrow Transplant. Elsevier, 2006. Vol. 12, N 2. P. 28.

112. de Latour R.P., Risitano A.M., Dufour C. Severe Aplastic Anemia and PNH//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 579 - 587.

113. Michonneau D., G. GVHD Prophylaxis (Immunosuppression)//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 177 - 183.

114. Nagler A., Shimoni A. Conditioning//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 99 - 109.

115. Baron F. et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation//Haematologica. 2017. Vol. 102, N 2.

116. Basak G.W. Gastrointestinal Complications//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 2019. P. 381 - 386.

117. Chaturvedi S., George B., Savani B.N. Bleeding and Thrombotic Complications//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 2019. P. 301 - 306.

118. Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group//Am. J. Clin. Oncol. 1982. Vol. 5, N 6. P. 649 - 655.

119. Gratwohl A. The EBMT risk score//Bone Marrow Transplantation. Nature Publishing Group, 2012. Vol. 47, N 6. P. 749 - 756.

120. Sorror M.L. et al. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study//Biol. Blood Marrow Transplant. Elsevier Inc., 2015. Vol. 21, N 8. P. 1479 - 1487.

121. Сопроводительная терапия при лечении заболеваний системы крови. Практическое руководство/под ред. Е.Н. Паровичниковой, Г.М. Галстяна. М.: Практика, 2024. 512 с.

122. Трансплантация аллогенных гемопоэтических стволовых клеток. Практическое руководство. Под ред. Е.Н. Паровичниковой, Т.В. Гапоновой, М.Ю. Дрокова. - М.: Практика, 2024. - 640 с.

123. Дроков М.Ю, Моисеев И.С., Олейник Ю.А. Эффективность и безопасность метода трансплантации аллогенных гемопоэтических стволовых клеток и костного мозга у взрослых пациентов с заболеваниями системы крови: опрос экспертов трансплантационных центров Российской Федерации, CTT JOURNAL, March (13) с. 49 - 92

124. Scheinberg P, Rios O, Scheinberg P, Weinstein B, Wu CO, Young NS. Prolonged cyclosporine administration after antithymocyteglobulin delays but does not prevent relapse in severe aplastic anemia. Am J Hematol. 2014; 89(6): 571 - 4.

125. Peffault de Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, et al. Eltrombopag added to immunosuppression insevere aplastic anemia. N Engl J Med. 2022; 386(1): 11 - 23